MAXIMUS, Inc.
MMS
$66.66
+4.24%
MAXIMUS, Inc. is a specialized business services company that designs, develops, and delivers programs enabling access to vital government services, primarily in the health and human services sectors. It operates as a key government contractor, translating public policy into operational models for large-scale eligibility, enrollment, clinical assessments, and technology solutions. The current investor narrative centers on a challenging operational and financial transition, as evidenced by recent quarterly revenue declines and a significant stock price correction following its latest earnings report, raising questions about contract execution and future growth visibility in its core government markets.…
MMS
MAXIMUS, Inc.
$66.66
Investment Opinion: Should I buy MMS Today?
Rating: Hold. The core thesis is that MAXIMUS presents a high-risk, high-potential-reward situation where deeply depressed valuation meets clear fundamental deterioration, creating an asymmetric bet best suited for patient, risk-tolerant investors awaiting a turnaround signal.
Supporting evidence includes a forward P/E of 7.18x that prices in significant pessimism, a robust FCF yield of 4.2% providing financial flexibility, and analyst EPS expectations of $9.115 implying a powerful earnings rebound. However, these positives are counterbalanced by a -4.11% YoY revenue decline, compressing margins, and catastrophic technical performance (-33.6% over 3 months). The stock trades at a discount to its own history (trailing P/E of 16.44x) and on a Price/Sales basis (0.97x), but these metrics may be justified by the deteriorating growth profile.
The thesis would upgrade to a Buy if the company demonstrates sequential revenue stabilization and margin improvement in the next quarterly report, confirming the downturn is bottoming. It would downgrade to a Sell if revenue decline accelerates beyond -5% YoY or if free cash flow generation meaningfully deteriorates. Currently, the stock is fairly valued relative to its near-term challenged prospects but undervalued if a multi-year recovery materializes.
Sign up to view all
MMS 12-Month Price Forecast
The investment case for MMS is a clash between valuation and momentum. The valuation is compellingly cheap, but the price and fundamental momentum are decisively negative. The neutral stance reflects this standoff; the stock is not a buy until operational trends inflect positively, but its deep value characteristics make it difficult to justify an outright sell. Confidence is medium because the limited analyst coverage adds uncertainty to forward estimates. The stance would upgrade to bullish on concrete evidence of revenue stabilization; it would downgrade to bearish on another quarter of accelerating decline.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on MAXIMUS, Inc.'s 12-month outlook, with a consensus price target around $86.66 and implied upside of +30.0% versus the current price.
Average Target
$86.66
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$53 - $87
Analyst target range
Analyst coverage for MMS is extremely limited, with only two analysts providing estimates, indicating this is a stock with minimal institutional research attention, which can lead to higher volatility and less efficient price discovery. The consensus leans bullish based on the available data, with an average EPS estimate of $9.115 for the coming period, implying significant earnings growth from the trailing figure. The target price range derived from revenue estimates is wide, spanning from $5.61 billion to $5.81 billion, reflecting high uncertainty around the company's near-term revenue trajectory and the impact of recent operational challenges.
Bulls vs Bears: MMS Investment Factors
The evidence currently tilts bearish, as concrete financial deterioration (revenue decline, margin compression) and catastrophic technical damage outweigh the compelling valuation discount. The bear case is supported by observable negative trends, while the bull case relies on a future recovery that is not yet evident in the reported numbers. The single most important tension in the investment debate is whether the current forward P/E of 7.18x represents a profound mispricing of a temporary downturn or an accurate pricing of a permanent impairment to the business model. The resolution hinges on the next few quarters of revenue and margin performance.
Bullish
- Extreme Valuation Discount: The stock trades at a forward P/E of just 7.18x, a deep discount to its own trailing P/E of 16.44x and likely below sector averages, implying the market expects severe earnings deterioration. This low multiple, combined with a Price/Sales ratio of 0.97, suggests the stock is priced for failure, leaving significant room for a re-rating if the company stabilizes.
- Strong Free Cash Flow Generation: Despite revenue declines, the company generated $218.5 million in trailing twelve-month free cash flow, yielding a robust FCF yield of approximately 4.2%. This provides ample cash to service its moderate debt (D/E of 0.86), fund its dividend (yield of 1.31%), and navigate the current transition without liquidity stress.
- Analyst EPS Expectations Signal Recovery: The average analyst EPS estimate for the coming period is $9.115, which implies a substantial recovery from recent quarterly results. This forward optimism, albeit from only two analysts, suggests the current operational challenges are viewed as temporary, with a path to significantly higher profitability.
- Oversold Technical Condition: The stock is down 33.6% over three months and trades at just 48% of its 52-week range ($65.47 vs. high of $100), near its 52-week low of $60.75. This extreme sell-off, coupled with a historical beta of 0.625, indicates the decline is driven by company-specific pessimism, potentially creating a contrarian opportunity if fundamentals bottom.
Bearish
- Revenue Contraction and Margin Pressure: Recent quarterly revenue declined 4.11% YoY to $1.345B, continuing a decelerating trend. Concurrently, gross margin compressed to 22.18% from 23.15% a year ago, and net margin fell to 6.98% from 8.66%, indicating fundamental deterioration in both top-line growth and profitability.
- Severe and Sustained Price Downtrend: The stock has underperformed the S&P 500 by over 37 percentage points over the past three months and 35 points over the past year. This persistent negative momentum, with a maximum drawdown of -36.95%, reflects a clear loss of investor confidence and suggests the bad news may not be fully priced in.
- Limited Analyst Coverage and High Uncertainty: Only two analysts cover the stock, leading to less efficient price discovery and higher volatility. The wide estimated revenue range of $5.61B to $5.81B highlights significant uncertainty around the company's near-term trajectory and the impact of its operational challenges.
- Government Contract Dependency Risk: As a key government contractor, MAXIMUS's revenue is heavily reliant on public policy and funding cycles. The recent revenue decline suggests potential issues with contract execution, renewals, or funding, exposing the business to non-diversifiable political and budgetary risks that are difficult to predict.
MMS Technical Analysis
The stock is in a pronounced and sustained downtrend, having declined 25.36% over the past six months and 4.84% over the past year, starkly underperforming the broader market. With a current price of $65.47, it is trading at just 48% of its 52-week range ($60.75 to $100.00), positioning it near multi-year lows and signaling deep investor pessimism, though it may also be approaching an oversold condition. Recent momentum remains severely negative, with the stock down 33.59% over three months and 3.45% over one month, indicating the selling pressure has accelerated sharply from the longer-term trend, likely triggered by disappointing financial results. The stock's beta of 0.625 suggests it has been less volatile than the market historically, but the recent 36.95% maximum drawdown highlights extreme idiosyncratic risk. Key technical support is at the 52-week low of $60.75, while resistance is far above at the 52-week high of $100; a breakdown below $60.75 could trigger another leg down, whereas a recovery above the recent breakdown level near $78 would be needed to signal a potential trend reversal.
Beta
0.60
0.60x market volatility
Max Drawdown
-37.0%
Largest decline past year
52-Week Range
$61-$100
Price range past year
Annual Return
-0.7%
Cumulative gain past year
| Period | MMS Return | S&P 500 |
|---|---|---|
| 1m | +2.3% | +11.0% |
| 3m | -11.2% | +5.9% |
| 6m | -20.7% | +9.0% |
| 1y | -0.7% | +30.4% |
| ytd | -22.9% | +7.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MMS Fundamental Analysis
Revenue growth has stalled and turned negative, with the most recent quarterly revenue of $1.345 billion representing a 4.11% year-over-year decline, continuing a trend of sequential deceleration from the prior quarter's $1.318 billion. Segment data indicates the Clinical Services business, at $523.7 million, is the primary revenue driver, though specific growth rates for segments are not available to pinpoint the exact source of weakness. The company remains profitable with a net income of $93.9 million for the quarter, but profitability metrics show pressure, as the net margin of 6.98% and gross margin of 22.18% have compressed from the year-ago quarter's margins of 8.66% and 23.15%, respectively. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.86, and a current ratio of 1.64 indicates sufficient short-term liquidity. Trailing twelve-month free cash flow is a healthy $218.5 million, yielding a robust FCF yield of approximately 4.2% based on market cap, suggesting the company generates ample cash to service debt and fund its dividend, despite the recent operational headwinds.
Quarterly Revenue
$1.3B
2025-12
Revenue YoY Growth
-0.04%
YoY Comparison
Gross Margin
+0.22%
Latest Quarter
Free Cash Flow
$218482000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MMS Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 16.44x, while the forward P/E is significantly lower at 7.18x, indicating the market expects a substantial recovery in earnings, though this low forward multiple also reflects deep skepticism and potentially lowered estimates. Compared to sector averages, the stock trades at a discount on a Price/Sales basis, with a PS ratio of 0.97, which is below the typical range for profitable service businesses, suggesting the market is assigning little value to its revenue base due to growth concerns. Historically, the stock's own trailing P/E of 16.44x is below its recent historical range observed in prior quarters (e.g., 17.1x in Q4 2025, 19.6x in Q4 2024), placing it at the lower end of its own valuation band, which could indicate a value opportunity if fundamentals stabilize, but may also price in expectations of further earnings deterioration.
PE
16.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's deteriorating fundamentals. The 4.11% YoY revenue decline and sequential margin compression (gross margin down 97 bps YoY) indicate operational headwinds that may not be transient. While free cash flow remains healthy at $218.5M TTM, a continuation of revenue declines could pressure this key strength. The business also carries concentration risk, with a majority of revenue derived from U.S. Federal government contracts, making it vulnerable to budgetary shifts and execution missteps on key programs.
Market & Competitive Risks are pronounced given the stock's valuation disconnect. While trading at a deep discount (forward P/E of 7.18x), this could compress further if earnings estimates are cut, representing a classic 'value trap' scenario. The stock's low beta of 0.625 suggests it should be defensive, yet its 36.95% max drawdown shows extreme idiosyncratic risk, likely from company-specific contract or operational issues. Competitive pressures in the government services sector could intensify, squeezing already declining margins.
Worst-Case Scenario involves a continuation of the current negative operational momentum, leading to further revenue declines, margin erosion, and analyst estimate downgrades. This could trigger a loss of dividend coverage confidence and a re-assessment of its government contract moat. The realistic downside could see the stock testing and breaking its 52-week low of $60.75, implying a further -7.2% decline from the current $65.47. In a severe bear case where the business model is questioned, a drop towards the $50-$55 range (a -15% to -25% decline) is plausible, aligning with a scenario where the forward P/E multiple fails to provide support due to collapsing earnings.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued revenue decline (-4.11% YoY) and margin compression, threatening the earnings recovery priced into the low forward P/E. 2) Sentiment & Liquidity Risk: With only two analyst covering the stock and severe negative price momentum, the stock is prone to exaggerated swings and inefficient price discovery. 3) Concentration Risk: Heavy reliance on U.S. Federal government contracts subjects revenue to political and budgetary uncertainty. 4) Financial Risk: While currently manageable, a debt-to-equity ratio of 0.86 could become burdensome if profitability continues to erode.
The 12-month forecast for MMS is highly bifurcated, with a base case target range of $65-$80 (50% probability), a bull case of $85-$100 (25% probability), and a bear case of $55-$65 (25% probability). The base case, which is most likely, assumes the company stabilizes its operations without a near-term growth catalyst, leaving the stock to trade on its deep-value metrics. The forecast hinges almost entirely on whether the next few quarterly reports show an inflection in revenue and margin trends. The wide range reflects the high uncertainty stemming from limited analyst coverage and recent operational missteps.
MMS appears statistically undervalued based on traditional metrics. Its forward P/E of 7.18x is less than half its trailing P/E of 16.44x and is exceptionally low for a profitable company. Its Price/Sales ratio of 0.97 also suggests a discount. However, this 'undervaluation' is justified by the company's current fundamental challenges—negative revenue growth and margin compression. The market is pricing in expectations of further earnings deterioration. Therefore, while the stock is cheap, it may be a 'value trap' rather than a true bargain until operational trends improve.
MMS is a high-risk, potentially high-reward stock that is not a good buy for most investors at this moment. It is trading at a deeply discounted forward P/E of 7.18x, suggesting significant upside if the company recovers, as analysts project EPS of $9.115. However, with revenue declining 4.11% YoY and the stock in a severe downtrend (down 33.6% in 3 months), the risk of further deterioration is high. It could be a good buy for very patient, risk-tolerant value investors who can withstand volatility and are confident in a long-term turnaround, but it is unsuitable for conservative portfolios.
MMS is unsuitable for short-term trading due to its low liquidity, limited coverage, and high volatility driven by company-specific news. Its low beta of 0.625 is misleading given its recent massive drawdown. The stock is only suitable for a long-term investment horizon of 3-5 years, allowing time for a potential operational turnaround to unfold and for the deep valuation discount to be recognized. The healthy free cash flow and dividend provide a small income stream for long-term holders, but the primary thesis is capital appreciation from a successful business recovery, which will take multiple quarters to confirm.